CA-INSEEGO-CORP
25.3.2021 14:07:05 CET | Business Wire | Press release
Inseego Corp. (Nasdaq: INSG), a leader in 5G and IoT device-to-cloud solutions, today announced that its Wavemaker PRO 5G outdoor CPE FW2000e has been certified for use in Europe and the U.S., including FCC Band 48 support for CBRS networks and the newly auctioned C-band spectrum. Operators and enterprise users can now deploy this high-performance outdoor customer premise equipment (CPE) on their public and private networks to deliver reliable, high-speed 5G/LTE connectivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210325005307/en/
Purpose-built with high-gain antennas that maximize signal strength, the FW2000e extends the reach of cellular networks, providing fixed wireless access (FWA) for enterprise, SMB and residential users in urban, suburban or rural locations. Inseego Connect™ cloud softwarei makes it easy for operators and businesses to remotely configure and manage any number of FW2000e CPEs deployed across their networks.
“With the FW2000e, mobile operators can deliver a compelling wireless alternative for consumer and business end users who are underserved by wireline networks,” said Inseego President of IoT & Mobile Solutions Ashish Sharma. “Inseego is providing full-featured, future-proof 5G solutions for a wide array of markets that require secure and reliable broadband connectivity including industrial IoT and private network applications.”
Bringing 5G to underserved communities
According to the FCC, nearly one-fourth of the U.S. population in rural areas still lacks home broadband (at least 25 Mbps download speeds). Many schools, small businesses, clinics, farms and other sites are also underserved.
Using mid-band and low-band (sub-6 GHz) spectrum, wireless service providers can now bring high-speed 5G broadband access to these customers with speeds that can outperform typical wired connections. This also makes 5G fixed wireless access a compelling alternative for rural and suburban “cord cutters” who want to consolidate their internet and mobile services, all from one provider.
Of course, the digital divide is not just a U.S. concern, but a global challenge. The broad coverage and high speed made possible by sub-6 GHz 5G technology offers a solution for many regions. According to the GSA, over 60 countries have already launched commercial 5G networks and more than 131 countries are investing in 5G networks.
Connecting enterprise offices, private networks and industrial IoT
5G/LTE private networks and industrial IoT networks will grow rapidly in the next five years, covering corporate campuses, college campuses, smart cities, energy facilities, warehouses, banks, retailers, factories, entertainment venues and other locations. The FW2000e provides fast, reliable, secure broadband connectivity for public, private and hybrid networks in all these places, with software that makes it easy to deploy and remotely manage one or many endpoints. The FW2000e has been approved by the FCC to operate as a Category B CBSD (the highest CBSD power category, Category Broadband Radio Service Device) in the CBRS band.
Best-in-class 5G FWA performance
- Unsurpassed antenna gain for greater range and higher throughput at any distance — With a sophisticated antenna array and 4x4 MIMO (multiple input, multiple output) technology, the FW2000e delivers up to 14 dBi gain for a stronger signal even at the edge of cellular networks — and higher throughput at any distance. With multi-gigabit peakii speeds, it outperforms every other outdoor CPE device in its class.
- 5 Gbps ethernet LAN port with power-over-ethernet (POE) — Provides a high-speed gateway to indoor routers and other access points
- Broadest global band support — Built to operate on 18 different 5G bands and 24 LTE (Cat 22) bands
- Dual SIMs for multi-carrier flexibility and failover with auto-switching — Supports two carrier SIMs and auto-switching between carriers based on signal strength, data usage, service availability and other criteria. Multi-carrier firmware supports most major global carriers.
- Extreme reliability — IP67-rated durability for harsh environments and a wide range of operating temperatures
- Inseego Mobile app — User-friendly mobile app simplifies professional installation and device management. Intuitive step-by-step setup process includes a site survey to determine the optimal location and orientation. Also allows users to remotely configure device settings, manage connected devices, reboot and much more.
- Inseego Connect ™ device management — Integrated software solution for a single device included, plus tiered upgrade options for advanced device management, monitoring, diagnostics and security for multiple devices from a single dashboard.
Enterprise software features for a multi-carrier 5G managed WAN
More than a 5G/LTE connectivity device, the FW2000e is a full-featured, future-proof solution for enterprise customers that includes ongoing device management and security feature updates. Please contact Inseego for more details on base model and enterprise versions.
Availability
The Inseego Wavemaker™ 5G outdoor CPE FW2000e has received regulatory certifications for use in Europe and North America, with more certifications pending for other markets. This solution is now available to operators, and also to enterprise customers in North America and Europe through Inseego channel partners in both regions. Contact sales@inseego.com for details.
A broad portfolio of 5G FWA solutions
In addition to the FW2000e, the Inseego Wavemaker PRO portfolio includes the 5G outdoor CPE FW2010e (designed for mmWave spectrum), which is currently in field trials with multiple customers. The portfolio also includes two 5G indoor routers and a 5G industrial gateway. Please contact Inseego to learn more about these solutions.
Trusted and secure
Designed and developed in the U.S., Inseego solutions are trusted by leading mobile operators, government agencies and enterprise customers worldwide. To learn more about Inseego 5G products and solutions go to inseego.com . For press and analyst inquires, please email press@inseego.com .
About Inseego Corp.
Inseego Corp. (Nasdaq: INSG) is an industry leader in smart device-to-cloud solutions that extend the 5G network edge, enabling broader 5G coverage, multi-gigabit data speeds, low latency and strong security to deliver highly reliable internet access. Our innovative mobile broadband, fixed wireless access (FWA) solutions and software platform incorporate the most advanced technologies (including 5G, 4G LTE, Wi-Fi 6 and others) into a wide range of products that provide robust connectivity indoors, outdoors and in the harshest industrial environments. Designed and developed in the USA, Inseego products and SaaS solutions build on the company’s patented technologies to provide the highest quality wireless connectivity for service providers, enterprises and government entities worldwide. www.inseego.com #Putting5GtoWork
©2021 Inseego Corp. All rights reserved. The Inseego name and logo are registered trademarks, and the Wavemaker and Inseego Manage names are trademarks of Inseego Corp. Other Company, product or service names mentioned herein are the trademarks of their respective owners.
___________________
i Base version (free) enables a user to manage a single FW2000 device settings easily using the Inseego Mobile app or Web UI. For management of multiple devices, an Inseego Connect Standard or Inseego Connect Advanced subscription is required, providing advanced device management, provisioning, monitoring and diagnostics for multiple devices from a single dashboard.
ii Theoretical max download and upload speeds. Actual speeds experienced are dependent on carrier network and coverage.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005307/en/
Social Media:
https://www.facebook.com/Inseego/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
